Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance

Launched by GENOMIC HEALTH®, INC. · Apr 17, 2018

Keywords

ClinConnect Summary

This is a multicenter observational study that evaluates eligible patients who will submit prostate cancer diagnostic biopsy tissues for Oncotype DX Prostate Cancer Assay testing. A physician treatment recommendation will be made and the assay is ordered. The physician will review clinical data, the GPS report and discuss treatment options with the patient. At the following visit, a shared physician-patient treatment decision (immediate treatment or AS) will be made.

Men selecting AS as primary treatment will be followed to assess persistence on AS.

There is no required or standardized AS...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Clinical stage T1c/T2
• • PSA ≤ 20ng/mL
• • Biopsy GS ≤ 6 with any number of cores positive, or Biopsy GS 3+4 disease with ≤3 positive cores or ≤ 33% positive cores
• • The patient must be ≥ 50 years of age
• • The patient must have a life expectancy of \> 10 years
• • Patient must be able to give consent in English or Spanish
• Exclusion Criteria:
• • Clinical stage T3a or above
• • PSA \> 20ng/mL
• • Biopsy GS 4+3 or \> 8
• • Known metastatic prostate cancer
• • Positive biopsy for prostate cancer \> 3 months ago
• • Treatment decision has already been made
• • Insufficient tumor in prostate biopsy tissue to perform the assay
• • Treatment with androgen deprivation therapy (ADT) prior to prostate biopsy
• • Diagnosis made by transurethral resection of prostate (TURP) shavings
• • Any psychiatric or psychological conditions
• • Contraindications to primary treatment according to physician's judgment